Approaches to improve adherence to pharmacotherapy in patients with schizophrenia

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 701-714

  Shuler, Kimberly M ^a  

^a Shuler Counseling and Consulting   (United States)

Author keywords

Community mental health services; Medication adherence; Psychiatric; Schizophrenia; Social work

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE;

ATTITUDE TO HEALTH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPLOYMENT; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICATION COMPLIANCE; MENTAL HEALTH SERVICE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SOCIAL SUPPORT; SOCIAL WORKER; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT REFUSAL;

EID: 84900807888     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S59371     Document Type: Review

References (50)

1. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry. 2008;42(5):382-388.
2. Hudson TJ, Owen RR, Thrush CR, etal. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2): 211-216.
3. Cortesi PA, Mencacci C, Luigi F, etal. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry. 2013;13:98.
4. Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275-284.
5. Farabee D, Shen H, Sanchez S. Program-level predictors of antipsychotic medication adherence among parolees. Int J Offender Ther Comp Criminol. 2004;48(5):561-571.
6. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011;3:9-14.
7. Rabinovitch M, Béchard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28-35.
8. Boardman GH, McCann TV, Clark E. Accessing health care professionals about antipsychotic medication related concerns. Issues Ment Health Nurs. 2008;29(7):739-754.
9. Lang K, Meyers JL, Korn JR, etal. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010;61(12):1239-1247.
10. DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.
11. Kotzè AM, van Delft WF, Roos JL. Continuity of care of outpatients with schizophrenia in Pretoria. S Afr J Psychiatr. 2010;16(3):80-83.
12. Bond GR, Drake RE, Mueser KT, Latimer E. Assertive community treatment for people with severe mental illness: critical ingredients and impact on patients. Dis Manage Health Outcomes. 2001;9(3): 141-159.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
14. San L, Bernardo M, Gómez A, Martinez P, González B, Peña M. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord J Psychiatry. 2013;67(1):22-29.
15. Gilmer TP, Dolder CR, Lacro JP, etal. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4): 692-699.
16. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-180.
17. Becker MA, Young MS, Ochshorn E, Diamond RJ. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health. 2007;34(3):307-314.
18. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509-516.
19. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res. 2006;144(2-3):177-189.
20. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003;54(5):719-723.
21. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103-108.
22. Velligan DI, Weiden PJ, Sajatovic M, etal. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-48.
23. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
24. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008;59(3): 315-317.
25. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231-239.
26. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
27. Kirson NY, Weiden PJ, Yermakov S, etal. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6): 568-575.
28. Purvis TL, Nelson LA, Elliott ES, etal. Outpatient adherence to risperidone long-acting injection following discharge from a state psychiatric hospital. Am J Pharm Benefits. 2011;3(5):284-290.
29. Olfson M, Marcus SC, Wilk J, West JC. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv. 2006;57(2):205-211.
30. Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ. 2010;13(2):185-192.
31. Kozuki Y, Schepp KG. Adherence and nonadherence to antipsychotic medications. Issues Ment Health Nurs. 2005;26(4):379-396.
32. Zeber JE, Grazier KL, Valenstein M, Blow FC, Lantz PM. Effect of a medication copayment increase in veterans with schizophrenia. Am J Manag Care. 2007;13(6 Pt 2):335-346.
33. Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A. The influence of perceived social support on medication adherence in first-episode psychosis. Can J Psychiatry. 2013;58(1):59-65.
34. McCann TV, Lu S. Medication adherence and significant others' support of consumers with schizophrenia in Australia. Nurs Health Sci. 2009;11(3):228-234.
35. Wilk JE, West JC, Marcus SC, Countis L, Regier DA, Olfson M. Family contact and the management of medication non-adherence in schizophrenia. Community Ment Health J. 2008;44(5):377-380.
36. Weiss KA, Smith TE, Hull JW, Piper AC, Huppert JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull. 2002;28(2):341-349.
37. Valenstein M, McCarthy JF, Ganoczy D, etal. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv. 2013;64(5):445-451, 451. e1.
38. Manuel JI, Covell NH, Jackson CT, Essock SM. Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? J Am Psychiatr Nurses Assoc. 2011;17(1):51-56.
39. Petersen L, Jeppesen P, Thorup A, etal. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ. 2005;331(7517):602.
40. Aagaard J, Müller-Nielsen K. Clinical outcome of assertive community treatment (ACT) in a rural area in Denmark: a case-control study with a 2-year follow-up. Nord J Psychiatry. 2011;65(5):299-305.
41. Karow A, Reimer J, König HH, etal. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012;73(3): e402-e408.
42. McHugo GJ, Bebout RR, Harris M, etal. A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness. Schizophr Bull. 2004;30(4):969-982.
43. Granholm E, Anthenelli R, Monteiro R, Sevcik J, Stoler M. Brief integrated outpatient dual-diagnosis treatment reduces psychiatric hospitalizations. Am J Addict. 2003;12(4):306-313.
44. Rodrigo C, Welgama S, Wijeratne T, Weligepola R, Rajapakse S, Jayananda G. A prospective cohort study on the role of nonspecialist staff in preventing relapses and improving clinic attendance of patients with schizophrenia. Indian J Psychiatry. 2013;55(1):74-76.
45. Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J Clin Psychiatry. 2008;69(1):74-80.
46. Chen J, Ascher-Svanum H, Nyhuis AW, etal. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Prefer Adherence. 2011;5:547-554.
47. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354-360.
48. McCann TV, Deans C, Clark E, Lu S. A comparative study of antipsychotic medication taking in people with schizophrenia. Int J Ment Health Nurs. 2008;17(6):428-438.
49. McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009;65(3):534-543.
50. Stroup TS, McEvoy JP, Lieberman JA. Revised PORT recommendations. Schizophr Bull. 2004;30(3):609-611.